Patents by Inventor Ick-Chan Kwon

Ick-Chan Kwon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9012230
    Abstract: The present disclosure relates to a sulfonated benzene compound emitting fluorescence by reaction with hydrogen peroxide, aqueous-dispersed fluorescent nanoprobes applicable for real-time detection of hydrogen peroxide, and a fluorescent nanoprobe fabrication method. The fluorescent nanoprobe contains the following sulfonated benzene compound and water.
    Type: Grant
    Filed: January 31, 2012
    Date of Patent: April 21, 2015
    Assignee: Korea Institute of Science and Technology
    Inventors: Sehoon Kim, Ick Chan Kwon, Jai Kyeong Kim, Chang-Keun Lim, Jeongyun Heo
  • Patent number: 8957186
    Abstract: The present invention relates to a recombinant protein for siRNA delivery, which allows the efficient intracellular and in vivo delivery of siRNA. More particularly, the present invention relates to a recombinant protein that allows a siRNA binding protein to be located in the interior cavity of a capsid protein of HBV (Hepatitis B virus), in which siRNAs of interest bind to the siRNA binding protein to be encapsulated within the capsid shell, thereby providing stability against the external attack such as nucleases and achieving the efficient intracellular and in vivo delivery of siRNA by its release into the cytosolic space after cell uptake.
    Type: Grant
    Filed: December 7, 2011
    Date of Patent: February 17, 2015
    Assignee: Korea Institute of Science and Technology
    Inventors: Hyung-Jun Ahn, Ick-Chan Kwon, Kui-Won Choi
  • Publication number: 20150038690
    Abstract: Disclosed is a gelatin-based nanoparticle complex for tumor-targeted delivery of siRNA for specific gene silencing in tumor cells. The gelatin-based nanoparticle complex includes: poly-siRNA chains whose ends are modified with thiol groups; and thiolated gelatin bound to the poly-siRNA chains through disulfide crosslinking and charge interactions. The gelatin-based nanoparticle complex is not degraded in the bloodstream and can be efficiently absorbed into tumor cells without cytotoxicity. The delivered siRNA can effectively silence target gene expression. Also disclosed is a method for preparing the gelatin-based nanoparticle complex.
    Type: Application
    Filed: July 25, 2014
    Publication date: February 5, 2015
    Inventors: Kwang Meyung KIM, Sun Hwa KIM, Ick Chan KWON, Ji Young YHEE, Sojin LEE
  • Patent number: 8916685
    Abstract: The present invention relates to a fusion protein comprising small heat shock protein, a cage protein formed thereby, and novel use thereof, more particularly, a fusion protein comprising a small heat shock protein, a recognition site of a protease, and a histidine polymer, wherein the recognition site and the histidine polymer are sequentially linked to a carboxyl terminal of the small heat shock protein, a cage protein formed thereby, and novel use thereof. The fusion protein of the present invention, and a cage protein formed by the self-assembly properties of the fusion protein are not cytotoxic, and emits a fluorescence signal of about 20 to about 50 times higher comparing to a single peptide for the conventional molecular imaging, per unit protein. Additionally, cell permeability is very excellent, thereby to be effectively used as a biosensor or a bioactive material carrier.
    Type: Grant
    Filed: June 7, 2011
    Date of Patent: December 23, 2014
    Assignee: Korea Institute of Science and Technology
    Inventors: Hyung-Jun Ahn, Ick-Chan Kwon, Kul-Won Choi
  • Patent number: 8889647
    Abstract: Recombinant proteins for siRNA delivery and a composition including same. These recombinant proteins include a p19 RNA binding protein and a target oriented peptide and can secure the stability of siRNAs from external attacks such as various degradation enzymes, have selective binding affinity to cancer cells by virtue of target-oriented peptides having various cancer cells as their target, and silence target genes by effectively delivering the siRNAs to cells and biological tissues by the release of the siRNAs to the cytoplasms after the cell penetration thereof. Therefore, they are expected to be effectively employed as siRNA delivery vehicles for siRNA therapeutic agents, cell-based drug screening compositions and research.
    Type: Grant
    Filed: January 16, 2013
    Date of Patent: November 18, 2014
    Assignee: Korea Institute of Science and Technology
    Inventors: Hyung-Jun Ahn, Ick-Chan Kwon, Kui-Won Choi
  • Publication number: 20140288300
    Abstract: Disclosed is a drug-fluorophore complex for specific detection of tumor cells. Specifically, the drug-fluorophore complex includes a tumor cell-targeting drug penetrating tumor cells and non-tumor cells at different rates or levels, and a fluorescent substance chemically bonded to the tumor cell-targeting drug. The drug-fluorophore complex enables specific imaging of tumor cells only with high accuracy in a very simple manner without causing cytotoxicity.
    Type: Application
    Filed: July 8, 2013
    Publication date: September 25, 2014
    Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Kwang Meyung KIM, Ick Chan KWON, Sang Yoon KIM, Ju Hee RYU, Eun Sung JUN, In San KIM
  • Patent number: 8841085
    Abstract: Disclosed are a nanoparticle sensor for measuring protease activity, for protease imaging, and a method for preparing the same. More specifically, the present invention relates to a nanoparticle sensor for measuring protease activity in which a fluorophore- and a quencher-conjugated peptide substrate is conjugated to a biocompatible polymer nanoparticle. The peptide substrate is specifically lysed by a protease. The sensor according to the present invention is capable of inhibiting emission of fluorescence with high extinctive activity of the quencher on a fluorescent material. But strong fluorescence is specifically emitted only if the peptide substrate is lysed by a specific protease. Therefore, the sensor is especially useful as a method for screening a novel drug such as a protease overexpression inhibitor, and early diagnosis of incurable diseases and various diseases such as autoimmune diseases including cancer, osteoarthritis, rheumatoid arthritis and dementia.
    Type: Grant
    Filed: August 27, 2009
    Date of Patent: September 23, 2014
    Assignees: Korea Institute of Science and Technology, The Asan Foundation, Futurechem Co., Ltd.
    Inventors: Ick-Chan Kwon, Kui-Won Choi, Kwang-Meyung Kim, In-Chan Youn, Seul-Ki Lee, Kyeong-Soon Park, Dae-Hyuk Moon, Dae-Yoon Chi, Seung-Jin Lee, Seung-Jae Myung
  • Publication number: 20140147493
    Abstract: Disclosed is an efficient carrier for gene delivery to cells based on PCR. The PCR-based gene delivery carrier includes: a shell composed of neutral liposomes; and template DNA and PCR components including polymerase, dNTPs and primers for amplification of the template DNA by PCR, within an inner space defined by the shell. The gene delivery carrier enhances the gene loading efficiency of neutral liposomes without cytotoxicity. Further disclosed is a method for preparing the gene delivery carrier.
    Type: Application
    Filed: November 5, 2013
    Publication date: May 29, 2014
    Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Ick Chan KWON, Kwang Meyung KIM, Sun Hwa KIM, In-Cheol SUN, Jin Hee NA, Sangmin LEE, Ju Hee RYU
  • Publication number: 20140140934
    Abstract: Disclosed is a liver tumor-targeting ultrasound contrast agent. The ultrasound contrast agent includes a gas-generating core and a hyaluronic acid shell. The ultrasound contrast agent can be specifically delivered to liver cells. This specific delivery enables easy differentiation between normal liver cells and liver tumor cells by ultrasound imaging. In addition, the ultrasound contrast agent is highly stable in aqueous condition and causes no cytotoxicity. Also disclosed is a method for preparing the ultrasound contrast agent.
    Type: Application
    Filed: November 8, 2013
    Publication date: May 22, 2014
    Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Kwang Meyung Kim, Ick Chan Kwon, Inchan Youn, Hyun Su Min, Hong Yeol Yoon, Jae Hyung Park
  • Patent number: 8666499
    Abstract: Disclosed are a system and a method for artificial nerve networking capable of restoring a damaged nerve and allowing selective detection, analysis, transmission and stimulation of a signal from the damaged nerve. The artificial nerve networking system according to an embodiment of the present disclosure includes: a first nerve conduit connected at one end of a damaged nerve; a second nerve conduit connected at the other end of the damaged nerve; and an artificial nerve networking unit electrically connected to the first nerve conduit and the second nerve conduit and recovering the function of the damaged nerve by transmitting and receiving a signal to and from the damaged nerve.
    Type: Grant
    Filed: June 22, 2011
    Date of Patent: March 4, 2014
    Assignee: Korean Institute of Science and Technology
    Inventors: In Chan Youn, Kui Won Choi, Jun Kyo Suh, Ji Yoon Kang, Jin Seok Kim, Jun Uk Chu, Ick Chan Kwon, Kwang Meyung Kim
  • Publication number: 20140045914
    Abstract: This invention relates to a recombinant protein for siRNA delivery and a composition comprising the same. The recombinant proteins for siRNA delivery of the invention can secure the stability of siRNAs from external attacks such as various degradation enzymes, have selective binding affinity to cancer cells by virtue of target-oriented peptides having various cancer cells as their target, and silence target genes by effectively delivering the siRNAs to cells and biological tissues by the release of the siRNAs to the cytoplasms after the cell penetration thereof. Therefore, they are expected to be effectively employed as siRNA delivery vehicles for siRNA therapeutic agents, cell-based drug screening compositions and research.
    Type: Application
    Filed: January 16, 2013
    Publication date: February 13, 2014
    Inventors: Hyung-Jun AHN, Ick-Chan KWON, Kui-Won CHOI
  • Patent number: 8614285
    Abstract: Disclosed is a novel photosensitizer based on polymer derivatives-photosensitizer conjugates for photodynamic therapy capable of being selectively accumulated in cancerous tissues and producing singlet oxygen or free radical by laser irradiation. The polymer derivatives-photosensitizer conjugates for photodynamic therapy are prepared as nano-sized particles, and have excellent selection and accumulation ratio for cancerous tissues. The photosensitizer conjugates can produce singlet oxygen or free radical by a specific laser wavelength. Owing to the excellent selection and accumulation ratio for cancerous tissues, the conjugates minimizes photo-cytotoxicity of the conventional photosensitizer having a low molecular amount. Accordingly, the conjugates are very useful as a photosensitizes for photodynamic therapy with reduced side effects and excellent therapeutic effectiveness.
    Type: Grant
    Filed: April 23, 2008
    Date of Patent: December 24, 2013
    Assignee: Korea Institute of Science and Technology
    Inventors: Ick-Chan Kwon, Kui-Won Choi, Kwang-Meyung Kim, In-Chan Youn, Jong-Ho Kim, Kyeong-Soon Park
  • Publication number: 20130338422
    Abstract: The present invention relates to an anticancer prodrug consisting of peptide of acetyl-SEQ ID NO: 1-linker-anticancer drug. The anticancer prodrug effectively provides an anticancer drug unstable in acid or base, such as doxorubicin, in a form of prodrug. Thus, the anticancer prodrug exists as a non-toxic inactive form when administered into the body, but effectively releases the anticancer drug as an active ingredient in the target area in the presence of caspase activated by radiation or UV treatment after administered into the body. Accordingly, the anticancer drug exhibits selective anticancer effects on cancer cells, thereby maximizing the therapeutic effect and minimizing the side-effects of chemotherapy.
    Type: Application
    Filed: March 2, 2011
    Publication date: December 19, 2013
    Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Ju-Hee Ryu, Kwang-Meyung Kim, Ick-Chan Kwon, Kui-Won Choi, Sang-Yoon Kim, Beom-Suk Lee, Dae-Yoon Chi, Hee-Seup Kil, Hyun-Ju Sung
  • Publication number: 20130323177
    Abstract: A tumor-targeting gas-generating nanoparticle, a method for preparing same and a tumor-targeting nanoparticle for drug delivery using same relate to a tumor-targeting gas-generating nanoparticle including a polycarbonate core and a amphiphilic coat, a method for preparing same and a tumor-targeting nanoparticle for drug delivery using same. Since a tumor-targeting gas-generating nanoparticle according to the present disclosure is accumulated in the tumor tissue in large quantity and generates strong ultrasound wave signals, it can be usefully used as a contrast agent for ultrasonic imaging.
    Type: Application
    Filed: May 31, 2013
    Publication date: December 5, 2013
    Inventors: Ick Chan Kwon, Kwang Meyung Kim, Kuiwon Choi, Heebeom Koo, Hyun Su Min, Inchan Youn
  • Publication number: 20130273519
    Abstract: The present invention relates to a composition for treating blood, a set of a diagnostic kit comprising the same to detect an autoimmune disease, and a method of monitoring an autoimmune disease using the same. An autoimmune disease such as rheumatoid arthritis can be early diagnosed, and disease progression and a treatment response can be precisely predicted, using a technique of amplifying enzyme by stimulating blood obtained from patient.
    Type: Application
    Filed: November 5, 2012
    Publication date: October 17, 2013
    Inventors: In Chan Youn, Kwang Meyung Kim, Kui Won Choi, Ick Chan Kwon, Jun Uk Chu, Jong Woong Park, Soo Young Yoon, Sung Jae Choi, Ae Ju Lee, Young Mo Kang
  • Patent number: 8551727
    Abstract: Disclosed are a metal nanoparticle onto which a peptide substrate specifically degraded by protease and fluorophore are chemically modified for selectively imaging protease expressed in cell and in tissue in a human body, and the use thereof. Also, a quantitative analysis method of protease using the metal nanoparticle, a cell imaging method and a drug screening method of inhibiting a protease overexpression are provided. In detail, the present invention is directed to a metal nanoparticle having a peptide substrate and fluorophore coupled thereto, the peptide substrate and the fluorophore being specifically degraded by due to a protease activated in various ways in cell and in a human body to exhibit fluorescence. Hence, the metal nanoparticle can be used to rapidly screen activation and inhibition of the protease in the imaging manner.
    Type: Grant
    Filed: April 10, 2008
    Date of Patent: October 8, 2013
    Assignee: Korea Institute of Science and Technology
    Inventors: Ick-Chan Kwon, Kui-Won Choi, Kwang-Meyung Kim, Cheol-Hee Ahn, In-Chan Youn, Seul-Ki Lee, Kyeong-Soon Park
  • Publication number: 20130251784
    Abstract: The present disclosure relates to a method for in vivo targeting of a nanoparticle via bioorthogonal copper-free click chemistry, more particularly to a method for in vivo targeting of a nanoparticle, including: injecting a precursor capable of being metabolically engineered in vivo when injected into a living system and having a first bioorthogonal functional group into the living system; and injecting a nanoparticle having a second bioorthogonal functional group which can perform a bioorthogonal copper-free click reaction with the first bioorthogonal functional group attached thereto into the living system. In accordance with the present disclosure, accumulation of nanoparticles at a target site in a living system can be increased remarkably and the biodistribution of the nanoparticles can be controlled since the nanoparticles bound to a cell surface are taken up into the cell with time.
    Type: Application
    Filed: February 22, 2013
    Publication date: September 26, 2013
    Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Kwang Meyung KIM, Ick Chan KWON, Kuiwon CHOI, Heebeom KOO, Sang-min LEE, Inchan YOUN
  • Patent number: 8541378
    Abstract: The present invention relates to recombinant albumins fused with poly-cysteine peptide and methods for preparing the same, more precisely recombinant albumins in which cysteines that can be used for drug binding are amplified at N-terminal and C-terminal of the albumin and methods for preparing the same. The recombinant albumin of the present invention demonstrates improved albumin-drug conjugation efficiency when it is used for drug delivery system, indicating that it can effectively deliver a large amount of drug to a target tissue. At the same time, the recombinant albumin of the present invention can be used as an excellent drug deliverer with reduced side effects, compared with the conventional albumin carriers, by regulating the amount of drug conjugated to each unit of albumin by regulating the number of cysteine fused thereto.
    Type: Grant
    Filed: June 2, 2010
    Date of Patent: September 24, 2013
    Assignee: Korea Institute of Science and Technology
    Inventors: Hyung Jun Ahn, Ick Chan Kwon, Kuiwon Choi, Kwangmyeng Kim, Inchan Youn, Sehoon Kim
  • Patent number: 8530047
    Abstract: The oligonucleotide polymerization method of the present invention is advantageous in that an oligonucleotide with a small molecular weight can be easily polymerized into high-molecular weight oligonucleotides. Further, the high-molecular oligonucleotide prepared by the method of the present invention can bind to hydrophilic high-molecular materials or inorganic materials, and then can be stably delivered to a living body. Therefore, the high-molecular oligonucleotide prepared by the method of the present invention can be widely used for treating various diseases.
    Type: Grant
    Filed: March 2, 2010
    Date of Patent: September 10, 2013
    Assignee: Korea Institute of Science and Technology
    Inventors: KwangMeyung Kim, Ick Chan Kwon, Kui Won Choi, Seung Young Lee, In Chan Youn, Myung Sook Huh, So Jin Lee
  • Publication number: 20130230562
    Abstract: The present invention relates to a fusion protein comprising small heat shock protein, a cage protein formed thereby, and novel use thereof, more particularly, a fusion protein comprising a small heat shock protein, a recognition site of a protease, and a histidine polymer, wherein the recognition site and the histidine polymer are sequentially linked to a carboxyl terminal of the small heat shock protein, a cage protein formed thereby, and novel use thereof. The fusion protein of the present invention, and a cage protein formed by the self-assembly properties of the fusion protein are not cytotoxic, and emits a fluorescence signal of about 20 to about 50 times higher comparing to a single peptide for the conventional molecular imaging, per unit protein. Additionally, cell permeability is very excellent, thereby to be effectively used as a biosensor or a bioactive material carrier.
    Type: Application
    Filed: June 7, 2011
    Publication date: September 5, 2013
    Inventors: Hyung-Jun Ahn, Ick-Chan Kwon, Kul-Won Choi